Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
July 28 2011 - 6:00AM
PR Newswire (US)
THE WOODLANDS, Texas,
July 28, 2011 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company
focused on discovering breakthrough treatments for human disease,
announced today that it has successfully completed a Phase 1
clinical trial of LX1033, an orally-delivered small molecule drug
candidate for diarrhea-predominant irritable bowel syndrome
(IBS-d). Lexicon plans to move LX1033 forward into a Phase 2
study in patients with IBS-d.
Top-line results demonstrated that LX1033 was well tolerated at
all doses and produced a statistically significant reduction in
serotonin synthesis compared to placebo, as measured by both plasma
(p
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024